Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
12 September 2022 - 09:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the Month of September 2022
Commission File Number: 001-39997
Adagene Inc.
(Exact Name of Registrant as Specified in Its Charter)
4F, Building C14, No. 218
Xinghu Street, Suzhou Industrial Park
Suzhou, Jiangsu Province, 215123
People’s Republic of China
+86-512-8777-3632
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file
annual reports under cover of Form 20-F or Form 40-F.
Form 20-F x
Form 40-F o
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(1): o
Indicate by check mark if the registrant is submitting the
Form 6-K in paper as permitted by Regulation S-T
Rule 101(b)(7): o
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
| |
Adagene
Inc. |
| |
|
|
| |
By: |
/s/ Peter (Peizhi) Luo |
| |
Name: |
Peter (Peizhi) Luo |
| |
Title: |
Chief Executive
Officer |
| |
|
|
|
Date: September 12, 2022
|
|
|
EXHIBIT INDEX
| Exhibit |
|
Description |
| |
|
|
| 99.1 |
|
Press
Release titled “Adagene Presents Interim Monotherapy Data at ESMO
2022 Showing Compelling Safety, Anti-Tumor Activity and
Pharmacokinetics of Masked, Anti-CTLA-4 SAFEbody® ADG126 in
Patients with Advanced Tumors”
|
Adagene (NASDAQ:ADAG)
Historical Stock Chart
From Mar 2023 to Apr 2023
Adagene (NASDAQ:ADAG)
Historical Stock Chart
From Apr 2022 to Apr 2023
